Source: Business Wire

Press Release: Vivasure : Vivasure Medical Announces 100th Patient Enrolled in U.S. Pivotal Study

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the 100th patient in its PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal® Closure Device System. The U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval earlier this year to advance the PATCH study forward.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Andrew Glass's photo - CEO of Vivasure

CEO

Andrew Glass

CEO Approval Rating

90/100

Read more